Moreover, the GR antagonist, RU486 or mifepristone, has been suggested to be a normal breast epithelium protector [31], and in this context, there is an ongoing clinical trial based on the activity of RU486 in patients with breast cancer genes 1/2 (BRCA1/2) (clinical trial identifier NCT01898312). The gene discussed is NR3C1; the disease is breast carcinoma.